Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential for this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. José Baselga, M.D., Ph.D., associate director, chief of hematology/oncology, Massachusetts General Hospital Cancer Center, and Lewis C. Cantley, Ph.D., director, Cancer Center at Beth Israel Deaconess Medical Center, moderated a press conference about this research Wednesday, Nov. 9, 2011. Drs. Baselga and Cantley are co-editors of Cancer Discovery. Read the press release and listen to the teleconference.
Download* the mp3 of the teleconference (49.6 MB, 54:11 min.)
*On a PC, right mouse click on the "Download" link and select "Save link as..." in Firefox or "Save Target as..." in Internet Explorer.